Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 268.00 | |
50 mg | In stock | $ 497.00 | |
100 mg | In stock | $ 723.00 | |
500 mg | In stock | $ 1,520.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 108.00 |
Description | Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells. |
Targets&IC50 | PPARα(human):3.6 μM(EC50), PPARγ:0.2 μM(EC50), PPARα (rat):13.4 μM(EC50) |
In vivo | The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr(-/-)) mice. Tesaglitazar therapeutic group (n=15, 20 μg/kg/day oral treatment for 6 weeks). Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice and significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.[1] |
Molecular Weight | 408.47 |
Formula | C20H24O7S |
CAS No. | 251565-85-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 180.0 mg/mL (440.7 mM), ultrasonic and warming and heat to 60°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tesaglitazar 251565-85-2 DNA Damage/DNA Repair Metabolism PPAR inhibitor inhibit